Updated Preliminary Ph 1 Data and Registration-Enabling Plans for ERAS-0015 in KRAS-Mutant Solid Tumors Announced
“We believe the continued notable responses in patients with pancreatic cancer in the U.S., together with the encouraging data in lung cancer and early signal in combination with panitumumab in metastatic colorectal cancer that we have seen in Phase 1, underscore the broad potential of ERAS-0015 to become a foundational therapy for multiple RAS-mutant solid tumors,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “We look forward to additional preliminary monotherapy and combination data expected in the first half of 2027. We believe that we are well positioned to execute our robust clinical development plan and transition into Phase 3 development.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data